A correlative analysis of immune infiltrates within the SARC028 study (phase II trial of pembrolizumab in patients with advanced STS) reported a significantly higher proportion of PD-L1-expressing CD68+ TAMs at baseline among the responders (exclusively UPS and DDLPS) [15]. The gene discussed is CD68; the disease is telomere syndrome.